Yorvipath® (palopegteriparatide): rimborsabilità SSN AIFA dal 02/04/2026 per adulti con ipoparatiroidismo cronico non adeguatamente controllati con terapia convenzionale e teriparatide, o con controindicazioni a teriparatide.
ECTS 2026 Congress
Where cutting edge bone and mineral research meets a vibrant Catalan city As the European Calcified Tissue Society (ECTS) prepares for its 53rd Annual Congress, excitement is building around this year’s host city: Girona, Spain.From 24–27 April 2026, delegates from...
